The Nrf2-Keap1 signaling cascade has generated immense excitement over the last several years as progress has occurred with clinical trials of potential Nrf2 activators stemming from preclinical studies and research that has emerged as promising for patients with neurodegenerative disorders, multiple sclerosis, and psychiatric disorders. Here, NFE2L2 is linked to multiple sclerosis.